Current Status and Prospects of Immunotherapy for Osteosarcoma
Osteosarcoma is a malignant tumor with extreme invasiveness and metastasis as well as dismal prognosis. It is critical to rapidly find a unique therapy strategy capable of significantly improving the prognosis of osteosarcoma. Tumor immunotherapy has the potential to reawaken the immune system, rest...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2022-07-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1281 |
| _version_ | 1811223345422663680 |
|---|---|
| author | WU Wei JING Doudou CAO Li PU Feifei SHAO Zengwu |
| author_facet | WU Wei JING Doudou CAO Li PU Feifei SHAO Zengwu |
| author_sort | WU Wei |
| collection | DOAJ |
| description | Osteosarcoma is a malignant tumor with extreme invasiveness and metastasis as well as dismal prognosis. It is critical to rapidly find a unique therapy strategy capable of significantly improving the prognosis of osteosarcoma. Tumor immunotherapy has the potential to reawaken the immune system, restart and sustain the tumor-immune cycle in the body, resulting in the death of tumor cells. CD8+ CTL, CD4+ T cells, NK cells and NKT cells all play critical roles in tumor immunity, while humoral immunity may not only inhibit tumor growth but also enhance it. Researchers have devised various strategies to boost the immune system in recent years based on tumor immune response studies. This paper highlights and examines osteosarcoma immunotherapy from two perspectives: (1) boosting the response of patient's own immune system to the tumor; (2) exogenously improving the patient's immunological function. |
| first_indexed | 2024-04-12T08:31:18Z |
| format | Article |
| id | doaj.art-def524652dda425fb54431d76a781f55 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-04-12T08:31:18Z |
| publishDate | 2022-07-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-def524652dda425fb54431d76a781f552022-12-22T03:40:12ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782022-07-0149772172610.3971/j.issn.1000-8578.2022.21.12818578.2022.21.1281Current Status and Prospects of Immunotherapy for OsteosarcomaWU Wei0JING Doudou1CAO Li2PU Feifei3SHAO Zengwu4Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaOsteosarcoma is a malignant tumor with extreme invasiveness and metastasis as well as dismal prognosis. It is critical to rapidly find a unique therapy strategy capable of significantly improving the prognosis of osteosarcoma. Tumor immunotherapy has the potential to reawaken the immune system, restart and sustain the tumor-immune cycle in the body, resulting in the death of tumor cells. CD8+ CTL, CD4+ T cells, NK cells and NKT cells all play critical roles in tumor immunity, while humoral immunity may not only inhibit tumor growth but also enhance it. Researchers have devised various strategies to boost the immune system in recent years based on tumor immune response studies. This paper highlights and examines osteosarcoma immunotherapy from two perspectives: (1) boosting the response of patient's own immune system to the tumor; (2) exogenously improving the patient's immunological function.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1281osteosarcomatumor immune escapeimmunotherapy |
| spellingShingle | WU Wei JING Doudou CAO Li PU Feifei SHAO Zengwu Current Status and Prospects of Immunotherapy for Osteosarcoma Zhongliu Fangzhi Yanjiu osteosarcoma tumor immune escape immunotherapy |
| title | Current Status and Prospects of Immunotherapy for Osteosarcoma |
| title_full | Current Status and Prospects of Immunotherapy for Osteosarcoma |
| title_fullStr | Current Status and Prospects of Immunotherapy for Osteosarcoma |
| title_full_unstemmed | Current Status and Prospects of Immunotherapy for Osteosarcoma |
| title_short | Current Status and Prospects of Immunotherapy for Osteosarcoma |
| title_sort | current status and prospects of immunotherapy for osteosarcoma |
| topic | osteosarcoma tumor immune escape immunotherapy |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1281 |
| work_keys_str_mv | AT wuwei currentstatusandprospectsofimmunotherapyforosteosarcoma AT jingdoudou currentstatusandprospectsofimmunotherapyforosteosarcoma AT caoli currentstatusandprospectsofimmunotherapyforosteosarcoma AT pufeifei currentstatusandprospectsofimmunotherapyforosteosarcoma AT shaozengwu currentstatusandprospectsofimmunotherapyforosteosarcoma |